The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Targeting SLAMF6 upregulation in AML: development of a novel antibody
In this presentation, Carl Sandén, PhD, Lund University, Lund, Sweden, discusses the potential of targeting SLAMF6 as a novel mechanism to overcome immune evasion in acute myeloid leukemia (AML). Dr Sandén highlights that SLAMF6 upregulation is a common immune escape mechanism in AML, where it protects leukemia cells from immune cell-mediated killing. He then shares insights into an antibody being developed to target SLAMF6. This press briefing took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
